GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Parenterals Ltd

Sai Parenterals delays Q3 FY26 results filing by 23 days post-IPO

RESULTS ▼ Concern Flagged MEDIUM RISK
📅 Filed on BSE: 22 Apr 2026, 05:37 PM IST  ·  BSE ID: 98f1555f-409e-4f17-bfe3-8e983905de73
View Original BSE Filing (PDF)
💡
In Simple Terms
The company went public 19 days ago and is asking for more time to publish its latest quarterly earnings because it recently bought a company in Australia and needs their audit reports first.
🤖 AI Summary
  • Sai Parenterals requests 23-day extension to submit Q3 FY26 results — now due 15th May 2026
  • IPO listed 2nd April 2026; Regulation 33(3)(j) required results by 23rd April 2026
  • Delay driven by audits of recently acquired step-down subsidiary Noumed Pharmaceuticals PTY Limited, Australia
  • Subsidiary acquired 12th November 2025; audited financials expected first week of May 2026
  • FY26 audited results committed by 30th May 2026 under SEBI (LODR) requirements
🔢 Key Numbers — exact figures from BSE filing, not rounded
IPO listing date
2nd April 2026
Original results filing deadline under Reg 33(3)(j)
23rd April 2026
Revised Q3 FY26 results filing date
15th May 2026
Subsidiary acquisition date
12th November 2025
FY26 audited results commitment date
30th May 2026
Extension duration
23 days
🏢 How This Affects the Company
💰
Financial Impact
Filing delay postpones disclosure of Q3 FY26 standalone and consolidated financial results for the 9-month period ended 31st December 2025, deferring market visibility into post-IPO operating performance and consolidated impact of Noumed Pharmaceuticals acquisition.
⚙️
Operational Impact
Acquisition integration reporting requirements extend timeline — consolidation of Australian subsidiary financials into group results demands additional data compilation and audit coordination across geographies.
⚠️
Risk Impact
As a newly listed entity within 19 days of IPO, regulatory non-compliance with mandatory result submission timelines increases scrutiny from stock exchanges and SEBI, though company has formally requested and justified the extension.
👥 What This Means For Shareholders
✅
Action Required
No action required. Shareholders should note the revised results filing date of 15th May 2026 and FY26 audited results date of 30th May 2026 in their tracking calendars.
👤
Who Is Affected
All shareholders hold the company equally in terms of disclosure timing. The delay defers earnings visibility for all equity holders proportionally; newly listed retail and institutional investors relying on near-term result clarity are most affected.
🔍
Management Signal
Request for extension and explicit governance assurance indicate management awareness of regulatory obligations post-listing; however, timing miscalculation around acquisition integration suggests gaps in pre-IPO readiness planning.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY26 results filing by 15th May 2026 — verify consolidated financials include Noumed Pharmaceuticals
FY26 audited results release by 30th May 2026 — check segment contribution of acquired subsidiary
Q1 FY27 results filing — monitor if subsidiary integration improves reporting timelines and schedule adherence
MEDIUM RISK Recent IPO-phase regulatory delay signals operational or integration execution gaps; ongoing foreign subsidiary audit dependencies create execution timeline risk.
💡 Investor Takeaway
Sai Parenterals, listed 2nd April 2026, has requested extension until 15th May 2026 to file Q3 FY26 results. Delay stems from audits of Noumed Pharmaceuticals PTY Limited, Australia (acquired 12th November 2025), a step-down subsidiary. Consolidated result consolidation pending foreign subsidiary audit completion. No financial data disclosed in this filing.
⚖️ Strengths & Concerns

✅ Positives

  • Company proactively disclosed delay reason with specific subsidiary acquisition date and audit completion timeline.
  • Committed timeline for both Q3 results (15th May 2026) and FY26 audited results (30th May 2026) provides market clarity.

⚠️ Concerns

  • Regulatory delay in first 19 days post-IPO creates negative precedent for governance standards and timeliness expectations.
  • Consolidated result compilation dependencies on foreign subsidiary audit schedule introduce execution and timing risk.
📅 Company Track Record
Sai Parenterals listed on BSE (Scrip code 544742) on 2nd April 2026. No previous publicly available filing history prior to listing. Company is 19 days into public market listing as of this filing date (22nd April 2026).

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.